About US

Unify Pharmaceuticals is a biotech company utilizing the latest scientific discoveries to develop drugs targeting neurodegenerative diseases such as Parkinson’s Disease, Myocardial Infarction, Macular Degeneration, Alzheimer’s and Strokes. The company is the culmination of over 20 years’ research into UP-1007, the first-in-class water-soluble fullerene that has been shown to successfully target the underlying causes of Parkinson’s and other diseases involving oxidative damage. Unify has already received more than $25 M USD in funding from federal grants and philanthropic gifts.

Unify will be led by some of the brightest scientific minds in the world with a proven record of creating and developing the world’s most successful drugs:

Prof Laura Dugan – a neuroscientist at Vanderbilt University in Nashville, Tennessee, whose work on neurodegenerative diseases over the past two decades forms the basis for Unify’s business. A physician-scientist, Dugan has studied at some of the top scientific institutions in the world including MIT and Stanford.

Prof Sir Marc Feldmann – has initiated a major revolution in therapeutics; he initiated and developed the first successful monoclonal antibody therapy, anti-TNF.

Further developments in future uniting UP-1007 with cannabidiol (CBD) have the opportunity to provide effective and, most importantly, completely safe treatments for a number of diseases.

Prof Sir Marc Feldmann’s Unique Role in Drug Development

In 1990 Prof Sir Marc Feldmann visited Centocor to present the rationale for blocking TNF in rheumatoid arthritis. Reluctantly, they helped him and Sir Ravinder Maini test this with their antibody, now Infliximab (Remicade). The resulting success led to Centocor’s $4.9 B USD acquisition by Johnson & Johnson in 1999. Infliximab is now one of the world’s best-selling drugs, with sales of $7.152 B USD in 2017.

Feldmann and Maini are credited with creating the whole class of anti-TNF drugs. Several other companies used their pioneering research to underpin their own clinical trials.


Prof Sir Marc Feldmann


Publishes his hypothesis highlighting the role of cytokines in autoimmune diseases


Begins collaborating with Ravinder S. Maini on rheumatoid arthritis research


Published that anti-TNF normalized joint inflammation in vitro (Brennan et al, Lancet 1988)


First successful trials of Infliximab


Infliximab (Remicade) approved and released to the market

Centocor acquired by J&J for $4.9 B USD


Awarded the Crafoord prize with Maini for their work on anti-TNF therapy


Awarded the Albert Lasker award for Clinical Medical Research


Awarded the Cameron Prize for Therapeutics from the University of Edinburgh


Elected a fellow of the Royal Society


Awarded “European Inventor of the Year” by the European Patent Offices


Knighted by Prince Charles in the Queen’s Birthday Honours


Sir Marc Feldmann receives the Canada Gairdner International Award which is the highest scientific award in Canada


Remicade is the seventh-best-selling drug in the world with sales of $7.152 B USD

Prof Laura Dugan


Graduates from MIT, having begun work on graphite composite materials


Completes MD at Ohio State University


Begins clinical training & research on neurodegenerative diseases at Stanford University


Funding by the National Institute of Health begins


Joins Washington University, St Louis


First work published on the neuroprotective properties of UP-1007


First physician-scientist named as Chair in Geriatrics at UCSD


Named head of Division of Geriatric Medicine at Vanderbilt


Meets Prof Sir Marc Feldmann at the University of Oxford


Prof Dugan has received approx. $25 M USD in funding in Federal NIH and DoD grants, one SBIR, and several large philanthropic gifts

Targeting some of the world’s most common diseases






Utilizing the latest scientific discoveries